| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID1467: Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies |
|
Medicine details |
|
| Medicine name | elotuzumab (Empliciti®) |
| Formulation | 300 mg and 400 mg powder for concentrate for solution for infusion |
| Reference number | 3743 |
| Indication | In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/12/2019 |
| NICE guidance | |